Cambium Bio Limited (CMB), formerly Regeneus Ltd, is a Sydney-based clinical-stage regenerative medicine company. The company is dedicated to developing biologics for ophthalmology and tissue repair applications. Cambium Bio is focused on advancing its pipeline through clinical development and commercialisation, aiming to deliver transformative treatments that enhance patient outcomes.